Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Muscular weakness and/or muscle wasting is recognized as a key medical problem in critically ill patients on intensive care units (ICUs) worldwide.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and Results</h3><p>Intensive care unit‐acquired weakness (ICUAW) results from various diseases leading to critical illness and is observed in about 40% [1080/2686 patients, 95% confidence interval (CI): 38–42%] of mixed (medical–surgical) ICU patients. Muscle strength at ICU discharge is directly associated with mortality 5 years after discharge [hazard ratio 0.946, 95% CI: 0.928–0.968 per point increase in Medical Research Council (MRC) scores, <i>P</i> = 0.001]. ICUAW serves as umbrella term for the subgroups 'critical illness myopathy', 'critical illness polyneuropathy', and 'critical illness polyneuromyopathy', the latter distinguished using electrophysiology and/or biopsy studies. Diagnosing, studying, and developing treatments for ICUAW among the critically ill seems challenging due to the acuity and severity of the underlying heterogeneous diseases. Ventilator‐induced diaphragmatic dysfunction occurs in up to 80% (<i>n</i> = 32/40) of ICUAW patients after mechanical ventilation and mostly results from distinct muscular pathologies, disuse, underlying critical illness, and/or effects imposed directly by mechanical ventilation. Swallowing disorders/dysphagia likely represent an additional (local) neuromuscular dysfunction/ICUAW sequelae and presents in 10.3% (<i>n</i> = 96/933) of mixed medical–surgical ICU survivors, with 60.4% (<i>n</i> = 58/96) of patients remaining dysphagia positive until hospital discharge. Key independent risk factors for dysphagia following mechanical ventilation are baseline neurological disease [odds ratio (OR) 4.45, 95% CI: 2.74–7.24, <i>P</i> < 0.01], emergency admission (OR 2.04, 95% CI: 1.15–3.59, <i>P</i> < 0.01), days on mechanical ventilation (OR 1.19, 95% CI: 1.06–1.34, <i>P</i> < 0.01), days on renal replacement therapy (OR 1.1, 95% CI: 1–1.23, <i>P</i> = 0.03), and disease severity (Acute Physiology and Chronic Health Evaluation II score within first 24 h; OR 1.03, 95% CI: 0.99–1.07, <i>P</i> < 0.01). Dysphagia positivity independently predicts 28‐day and 90‐day mortality (90‐day univariate hazard ratio: 3.74; 95% CI, 2.01–6.95; <i>P</i> < 0.001) and is associated with a 9.2% excess (all‐cause) mortality rate. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Neuromuscular weakness and muscle wasting is observed in many survivors of critical illness. ICUAW, ventilator‐induced diaphragmatic dysfunction, and dysphagia are associated with complicated and prolonged ICU stay, impaired weaning from mechanical ventilation, impeded rehabilitative measures, and a considerable impact on morbidity and mortality is noted. Future research strategies should further explore underlying pathomechanisms and lead to development of causal treatment strategies.</p></section>

Neuromuscular manifestations of critical illness

The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill

Neurologic complications of critical illness: part II. Polyneuropathies and myopathies

Neurological complications of sepsis: critical illness polyneuropathy and myopathy

A prospective clinical study on the mechanisms underlying critical illness myopathy-A time-course approach

Critical Illness Polyneuropathy- And Myopathy: A Systematic Reviewu

Critical Illness Polyneuropathy and Myopathy： a Systematic Review

Clinical review: intensive care unit acquired weakness

Critical Illness Neuromyopathy and the Role of Physical Therapy and Rehabilitation in Critically Ill Patients

New Approaches to Critical Illness Polyneuromyopathy: High-Resolution Neuromuscular Ultrasound Characteristics and Cytokine Profiling

Pulmonary and Physical Rehabilitation in Critically Ill Patients

Muscular weakness and muscle wasting in the critically ill

Acute myopathy of intensive care: Clinical, electromyographic, and pathological aspects

The neurological complications of sepsis

Research Progress on Critical Illness Polyneuropathy and Critical Illness Myopathy

Risk Factors and Electromyographic Characteristics of Acquired Weakness in Critically Ill Patients: A Retrospective Study

Models of disuse muscle atrophy: therapeutic implications in critically ill patients

Case Report: Myopathy in Critically Ill COVID-19 Patients: A Consequence of Hyperinflammation?

Intensive care unit-acquired weakness: unanswered questions and targets for future research

Compound Muscle Action Potential and Myosin-Loss Pathology in Patients With Critical Illness Myopathy: Correlation and Prognostication

Critical illness neuropathy in severe COVID-19: a case series